Beckley PsyTech

Private Company

Company Logo

Company Overview

Beckley Psytech is dedicated to helping patients suffering from neurological and psychiatric disorders by developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines.

The company is focused on three distinct categories:

  • “1st Generation” Psychedelic Medicine: Progressing innovative formulations and applications of well-characterised psychedelic agents such as psilocybin and other compounds
  • “2nd Generation” Psychedelic Medicine: Developing known but under-researched psychedelic agents with potential clinical and patient access advantages over the first wave of psychedelic medicines
  • “3rd Generation” Psychedelic Medicine: Designing New Chemical Entities (NCEs) that improve upon existing psychedelics by providing better clinical and cost-efficacy outcomes

Management Team

Cosmo Feilding Mellen
Director & CEO

Dr. Steve Wooding
Chief Scientific Officer

Tim Mason
Chief Development Officer

Michael Norris
Chief Financial Officer

Kalpana Sawant
Director of Clinical Operations

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.